62.50

2.68% -1.7945

Ptc Therapeutics Inc (PTCT)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt PTCT? Forum Prognose

Schlusskurs vom Vortag:

$64.29

Offen:

$63.38

24-Stunden-Volumen:

378.07K

Relative Volume:

0.30

Marktkapitalisierung:

$5.17B

Einnahmen:

$900.66M

Nettoeinkommen (Verlust:

$-453.20M

KGV:

-10.52

EPS:

-5.94

Netto-Cashflow:

$-274.19M

1W Leistung:

-8.13%

1M Leistung:

-13.53%

6M Leistung:

+9.27%

1J Leistung:

+20.48%

1-Tages-Spanne:

$62.21

$64.50

1-Wochen-Bereich:

$62.21

$69.43

52-Wochen-Spanne:

$35.95

$87.50

Ptc Therapeutics Inc Stock (PTCT) Company Profile

Firmenname

Ptc Therapeutics Inc

Sektor

Healthcare (1111)

Branche

Biotechnology (621)

Telefon

(908) 222-7000

Adresse

500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ

Mitarbeiter

991

Twitter

@PTCBio

Nächster Verdiensttermin

2024-11-07

Neueste SEC-Einreichungen

PTCT's Discussions on Twitter

Compare PTCT vs VRTX, REGN, ARGX, ALNY, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
PTCT Ptc Therapeutics Inc	62.43	5.32B	900.66M	-453.20M	-274.19M	-5.94
VRTX Vertex Pharmaceuticals Inc	464.69	121.40B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	763.00	83.25B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	724.48	46.39B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	324.85	43.41B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	293.38	33.09B	5.36B	287.73M	924.18M	2.5229

Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-01-28	Fortgesetzt	Barclays	Overweight
2025-12-01	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2025-10-20	Eingeleitet	Wells Fargo	Overweight
2025-06-17	Eingeleitet	Truist	Buy
2025-05-09	Hochstufung	BofA Securities	Neutral → Buy
2025-05-07	Hochstufung	Citigroup	Sell → Neutral
2025-03-11	Hochstufung	BofA Securities	Underperform → Neutral
2025-03-07	Eingeleitet	Scotiabank	Sector Perform
2024-12-13	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2024-12-03	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2024-10-10	Fortgesetzt	Raymond James	Mkt Perform
2024-09-04	Eingeleitet	Robert W. Baird	Outperform
2024-08-26	Fortgesetzt	UBS	Buy
2024-05-20	Hochstufung	Raymond James	Underperform → Mkt Perform
2023-12-19	Herabstufung	Morgan Stanley	Equal-Weight → Underweight
2023-12-08	Eingeleitet	Wells Fargo	Overweight
2023-10-30	Hochstufung	Oppenheimer	Perform → Outperform
2023-10-27	Herabstufung	Citigroup	Neutral → Sell
2023-10-06	Herabstufung	Truist	Buy → Hold
2023-09-18	Herabstufung	Citigroup	Buy → Neutral
2023-09-15	Herabstufung	Raymond James	Outperform → Underperform
2023-03-17	Eingeleitet	SVB Securities	Market Perform
2022-12-14	Eingeleitet	Goldman	Sell
2022-09-12	Eingeleitet	Jefferies	Buy
2022-09-09	Eingeleitet	Morgan Stanley	Equal-Weight
2022-09-01	Eingeleitet	Citigroup	Buy
2022-04-04	Fortgesetzt	Cantor Fitzgerald	Overweight
2021-10-18	Herabstufung	BofA Securities	Neutral → Underperform
2021-04-26	Fortgesetzt	Credit Suisse	Neutral
2021-03-29	Hochstufung	RBC Capital Mkts	Underperform → Sector Perform
2021-02-12	Herabstufung	BofA Securities	Buy → Neutral
2021-01-05	Hochstufung	Citigroup	Neutral → Buy
2020-11-30	Herabstufung	RBC Capital Mkts	Sector Perform → Underperform
2020-10-30	Herabstufung	Citigroup	Buy → Neutral
2020-10-28	Eingeleitet	UBS	Neutral
2020-10-07	Hochstufung	JP Morgan	Neutral → Overweight
2020-08-25	Eingeleitet	Raymond James	Outperform
2020-04-09	Hochstufung	Citigroup	Neutral → Buy
2020-02-20	Herabstufung	Citigroup	Buy → Neutral
2020-02-20	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2019-11-12	Eingeleitet	SunTrust	Buy
2019-05-13	Hochstufung	BofA/Merrill	Neutral → Buy
2019-04-11	Eingeleitet	Bernstein	Outperform
2018-10-03	Hochstufung	BofA/Merrill	Underperform → Neutral
2018-10-01	Eingeleitet	Cantor Fitzgerald	Overweight
2018-07-19	Eingeleitet	Credit Suisse	Outperform
2018-06-18	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2018-04-04	Herabstufung	Barclays	Equal Weight → Underweight
2018-01-29	Fortgesetzt	RBC Capital Mkts	Sector Perform
2017-11-16	Hochstufung	JP Morgan	Underweight → Neutral
2017-10-26	Herabstufung	BofA/Merrill	Neutral → Underperform
2017-10-09	Herabstufung	JP Morgan	Neutral → Underweight

Alle ansehen

Ptc Therapeutics Inc Aktie (PTCT) Neueste Nachrichten

Mar 03, 2026

PTC Therapeutics Grants Stock Options and RSUs to New Employees - Intellectia AI

Mar 02, 2026

Assessing PTC Therapeutics (PTCT) Valuation After Contrasting Quarterly Loss And Full Year Profit Turnaround - Sahm

Mar 02, 2026

Mar 01, 2026

JPMorgan Chase & Co. Reduces Holdings in PTC Therapeutics, Inc. $PTCT - MarketBeat

Mar 01, 2026

Feb 28, 2026

PTC Therapeutics vs Merck: Which Is the Stronger Buy Today? - Trefis

Feb 28, 2026

Feb 27, 2026

GSA Capital Partners LLP Decreases Position in PTC Therapeutics, Inc. $PTCT - MarketBeat

Feb 27, 2026

PTCT Should I Buy - Intellectia AI

Feb 27, 2026

PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

Feb 27, 2026

Feb 26, 2026

16,062 Shares in PTC Therapeutics, Inc. $PTCT Purchased by Private Capital Advisors Inc. - MarketBeat

Feb 26, 2026